Luca Durelli

6.7k total citations · 1 hit paper
121 papers, 4.2k citations indexed

About

Luca Durelli is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Luca Durelli has authored 121 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pathology and Forensic Medicine, 43 papers in Neurology and 30 papers in Rheumatology. Recurrent topics in Luca Durelli's work include Multiple Sclerosis Research Studies (55 papers), Peripheral Neuropathies and Disorders (30 papers) and Systemic Lupus Erythematosus Research (23 papers). Luca Durelli is often cited by papers focused on Multiple Sclerosis Research Studies (55 papers), Peripheral Neuropathies and Disorders (30 papers) and Systemic Lupus Erythematosus Research (23 papers). Luca Durelli collaborates with scholars based in Italy, United States and Croatia. Luca Durelli's co-authors include Marinella Clerico, Roberto Mutani, Pierangelo Barbero, Bruno Ferrero, E. Verdun, Mauro Bergui, Massimo Filippi, Per Soelberg Sørensen, Frederik Barkhof and Óscar Fernández and has published in prestigious journals such as The Lancet, The Journal of Immunology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Luca Durelli

116 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

2001 757 citations Luca Durelli et al. profile →

Peers

Countries citing papers authored by Luca Durelli

Since Specialization

Citations

This map shows the geographic impact of Luca Durelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Durelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Durelli more than expected).

Fields of papers citing papers by Luca Durelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Durelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Durelli. The network helps show where Luca Durelli may publish in the future.

Co-authorship network of co-authors of Luca Durelli

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Durelli. A scholar is included among the top collaborators of Luca Durelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Durelli. Luca Durelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report (P2.091) 2016 ·Neurology ·Stefania De Mercanti, Luca Durelli, (unknown), Carlo Alberto Artusi, Pierangelo Barbero, Angelo Guerrasio, Marinella Clerico	0
2	Risk factors for tumor occurrence in patients with myasthenia gravis 2009 ·Journal of Neurology ·Antonietta Citterio, Ettore Beghi, Andrea Millul, Amelia Evoli, Renato Mantegazza, Carlo Antozzi, Fulvio Baggi, F. Cornelio, Luca Durelli, Marinella Clerico, G. Piccolo, Vittorio Cosi	26
3	Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b 2009 ·Expert Opinion on Biological Therapy ·Luca Durelli, Pierangelo Barbero, (unknown), Bruno Ferrero, (unknown), Giulia Contessa, Stefania De Mercanti, Paolo Ripellino, (unknown), (unknown), Mauro Bergui, Elisabetta Versino, Marinella Clerico	4
4	T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β 2009 ·Annals of Neurology ·Luca Durelli, Laura Conti, Marinella Clerico, Daniela Boselli, Giulia Contessa, Paolo Ripellino, Bruno Ferrero, Pierre Eid, Francesco Novelli	316
5	Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis 2008 ·Journal of Neurology ·Marinella Clerico, Fabrizio Faggiano, (unknown), Jackie Palace, G Rice, Luca Durelli	3
6	The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders 2008 ·Journal of Neurology ·Luca Durelli, Pierangelo Barbero, Mauro Bergui, Elisabetta Versino, (unknown), E. Verdun, Bruno Ferrero, Chiara Rivoiro, (unknown), (unknown), Paolo Ripellino, Denis Viglietti, Giorgio Giuliani, E. Montanari, Marinella Clerico, (unknown)	12
7	Interferon-β_1afor the treatment of multiple sclerosis 2007 ·Expert Opinion on Biological Therapy ·Marinella Clerico, Giulia Contessa, Luca Durelli	44
8	Evidence-based Medicine Analysis of Immunomodulatory Treatment for Multiple Sclerosis 2006 ·European Neurological Review ·Luca Durelli, A. Tavella, Giulia Contessa, Marinella Clerico	2
9	High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study 2004 ·Journal of the Neurological Sciences ·Pierangelo Barbero, E. Verdun, Mauro Bergui, (unknown), Marinella Clerico, (unknown), (unknown), B. Bergamasco, Luca Durelli	24
10	Immunoglobulin treatment of multiple sclerosis: future prospects 2003 ·Neurological Sciences ·Luca Durelli, (unknown), E. Verdun	3
11	Dose and frequency of interferon treatment matter 2003 ·Journal of Neurology ·Luca Durelli	10
12	Autoantibodies in Multiple Sclerosis Patients Before and During IFN- β 1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases? 2002 ·Journal of Interferon & Cytokine Research ·E. Verdun, G. Isoardo, Alessandra Oggero, Bruno Ferrero, Angelo Ghezzi, E. Montanari, Mauro Zaffaroni, Luca Durelli	27
13	High-dose intravenous immunoglobulin G treatment of myasthenia gravis 2002 ·Neurological Sciences ·Bruno Ferrero, Luca Durelli	17
14	Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study 2001 ·Journal of the Neurological Sciences ·Luca Durelli, Alessandra Oggero, E. Verdun, G. Isoardo, Pierangelo Barbero, B. Bergamasco, (unknown), Ezio Ghigo, Mauro Maccario, Fabrizio Faggiano	25
15	Terminal latency index in polyneuropathy with IgM paraproteinemia and anti‐MAG antibody 2001 ·Muscle & Nerve ·Dario Cocito, G. Isoardo, P. Ciaramitaro, Giuseppe Migliaretti, (unknown), Pierangelo Barbero, (unknown), Luca Durelli	47
16	Interferon-β dose and efficacy: the OPTIMS study 2001 ·Neurological Sciences ·Luca Durelli, Alessandra Oggero, E. Verdun, Pierangelo Barbero, (unknown), G. Isoardo, (unknown), Marinella Clerico, Gianni Boris Bradač, B. Bergamasco, Mauro Bergui	13
17	Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis 1996 ·Journal of the Neurological Sciences ·Maria Roberta Bongioanni, Luca Durelli, Bruno Ferrero, Daniele Imperiale, Alessandra Oggero, E. Verdun, Giuseppe Aimo, Roberto Pagni, Massimo Geuna, B. Bergamasco	15
18	Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis 1996 ·Neurology ·Luca Durelli, Maria Roberta Bongioanni, Bruno Ferrero, Renata Ferri, Daniele Imperiale, Gianni Boris Bradač, Mauro Bergui, Massimo Geuna, L Bergamini, B. Bergamasco	40
19	Human T Cell Intrathymic Ontogeny: Differences Between Myasthenic and Normal Thymus 1990 ·International Journal of Neuroscience ·Luca Durelli, (unknown), (unknown), Rossana Cavallo, (unknown), L Bergamini, G Maggi, Caterina Casadio, (unknown)	1
20	Carbamazepine Toxicity and Poisoning 1989 ·Drug Safety ·Luca Durelli, (unknown), (unknown)	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact